<DOC>
	<DOCNO>NCT01352273</DOCNO>
	<brief_summary>This multi- center , open-label , dose finding , Phase Ib study conduct two stage : dose escalation part determine maximum tolerate dose ( MTD ) safety tolerability concurrent administration MEK162 RAF265 , follow expansion part ass safety preliminary anti-tumor efficacy oral combination within two separate patient population : ) patient advance solid tumor harbor BRAFV600E mutation ii ) patient advance solid tumor harbor RAS mutation .</brief_summary>
	<brief_title>MEK162 RAF265 Adult Patients With Advanced Solid Tumors Harboring RAS BRAFV600E Mutations</brief_title>
	<detailed_description />
	<criteria>Patients histologically cytologically confirm nonresectable advanced solid tumor effective standard therapy exists . The patient ' tumor must contain documented activate somatic BRAFV600E* , NRAS KRAS mutation ( except pancreatic cancer ) All patient enrol MUST provide fresh archival tumor sample baseline enable central confirmation BRAF KRAS/NRAS mutation Measurable , nonmeasurable evaluable disease determine RECIST Adequate bone marrow function Adequate hepatic renal function Adequate cardiovascular function Negative serum β HCG test ( female patient childbearing potential ) within 72 hr prior first dose Patients history primary central nervous system tumor brain metastasis signs/symptoms attributable brain metastasis assess radiologic imaging rule presence brain metastasis Current evidence retinal disease ; ophthalmopathy assess ophthalmologic examination baseline would consider risk factor CSR/RVO ( e.g. , optic disc cupping , visual field defect , IOP &gt; 21 mm Hg ) Impaired cardio/vascular function clinically significant cardiovascular disease , include follow : History/evidence acute coronary syndrome ( include MI , unstable angina , CABG , coronary angioplasty , stenting ) ≤ 6 month prior start study drug Thromboembolic event ( DVT , CVA , PE ) ≤ 6 month prior start study Symptomatic CHF , history current evidence clinically significant cardiac arrhythmia and/or conduction abnormality Uncontrolled arterial hypertension , define BP &gt; 140/100 mmHg ( average 3 consecutive reading ) History melena , hematemesis hemoptysis within last 3 month Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/mL ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>advanced Solid tumor</keyword>
	<keyword>harbor RAS</keyword>
	<keyword>harbor BRAFV600E</keyword>
</DOC>